Cargando…

Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis

Introduction: Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment or structural lung disease to cause clinical disease. Fatal cavitary infection in a patient without immunosuppression is rarely presented. Case report: A 62-year-old female with hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulfattah, Omar, Salhan, Divya, Kandel, Saroj, Rahman, Ebad Ur, Dahal, Sumit, Alnafoosi, Zainab, Schmidt, Frances
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738639/
https://www.ncbi.nlm.nih.gov/pubmed/29296252
http://dx.doi.org/10.1080/20009666.2017.1407211
_version_ 1783287735933468672
author Abdulfattah, Omar
Salhan, Divya
Kandel, Saroj
Rahman, Ebad Ur
Dahal, Sumit
Alnafoosi, Zainab
Schmidt, Frances
author_facet Abdulfattah, Omar
Salhan, Divya
Kandel, Saroj
Rahman, Ebad Ur
Dahal, Sumit
Alnafoosi, Zainab
Schmidt, Frances
author_sort Abdulfattah, Omar
collection PubMed
description Introduction: Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment or structural lung disease to cause clinical disease. Fatal cavitary infection in a patient without immunosuppression is rarely presented. Case report: A 62-year-old female with history of sarcoidosis and hypertension presented with cough, fever and dyspnea for one week. Chest imaging showed irregular opacification of upper lung zones. The sputum samples tested positive for acid-fast bacilli (AFB) and the subsequent testing identified M. xenopi. She was started on rifampin, isoniazid, pyrazinamide and ethambutol along with azithromycin, and was discharged with plans to continue the same. A follow up sputum test was negative for AFB. She was, however, readmitted ten months later with sepsis due to pneumonia. Chest imaging revealed worsening cavitary lung lesions. Despite starting her on intravenous antibiotics while continuing anti-tubercular therapy, she developed severe respiratory distress and had to be intubated. Her condition continued to deteriorate and she expired the following day. Conclusion: Fatal cavitary infections with M. xenopi have been reported in the absence of established optimal management. Well-designed studies with sufficient power are needed to establish new treatment guidelines.
format Online
Article
Text
id pubmed-5738639
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-57386392018-01-02 Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis Abdulfattah, Omar Salhan, Divya Kandel, Saroj Rahman, Ebad Ur Dahal, Sumit Alnafoosi, Zainab Schmidt, Frances J Community Hosp Intern Med Perspect Case Report Introduction: Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment or structural lung disease to cause clinical disease. Fatal cavitary infection in a patient without immunosuppression is rarely presented. Case report: A 62-year-old female with history of sarcoidosis and hypertension presented with cough, fever and dyspnea for one week. Chest imaging showed irregular opacification of upper lung zones. The sputum samples tested positive for acid-fast bacilli (AFB) and the subsequent testing identified M. xenopi. She was started on rifampin, isoniazid, pyrazinamide and ethambutol along with azithromycin, and was discharged with plans to continue the same. A follow up sputum test was negative for AFB. She was, however, readmitted ten months later with sepsis due to pneumonia. Chest imaging revealed worsening cavitary lung lesions. Despite starting her on intravenous antibiotics while continuing anti-tubercular therapy, she developed severe respiratory distress and had to be intubated. Her condition continued to deteriorate and she expired the following day. Conclusion: Fatal cavitary infections with M. xenopi have been reported in the absence of established optimal management. Well-designed studies with sufficient power are needed to establish new treatment guidelines. Taylor & Francis 2017-12-14 /pmc/articles/PMC5738639/ /pubmed/29296252 http://dx.doi.org/10.1080/20009666.2017.1407211 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Abdulfattah, Omar
Salhan, Divya
Kandel, Saroj
Rahman, Ebad Ur
Dahal, Sumit
Alnafoosi, Zainab
Schmidt, Frances
Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
title Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
title_full Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
title_fullStr Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
title_full_unstemmed Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
title_short Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
title_sort fatal pulmonary cavitary disease secondary to mycobacterium xenopi in a patient with sarcoidosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738639/
https://www.ncbi.nlm.nih.gov/pubmed/29296252
http://dx.doi.org/10.1080/20009666.2017.1407211
work_keys_str_mv AT abdulfattahomar fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis
AT salhandivya fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis
AT kandelsaroj fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis
AT rahmanebadur fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis
AT dahalsumit fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis
AT alnafoosizainab fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis
AT schmidtfrances fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis